SCHEDULE 13G/A: Biotechnology Value Fund Entities Disclose 3.6% Stake in 89bio, Inc. via Schedule 13G Amendment
Beneficial Ownership Disclosure
Multiple entities associated with Biotechnology Value Fund, including BVF Partners L.P. and Mark N. Lampert, have collectively reported a beneficial ownership of 3.6% in 89bio, Inc. as of December 31, 2024, through an Amendment No. 4 to their Schedule 13G filing.
Summary
- As of December 31, 2024, Biotechnology Value Fund, L.P. (BVF) beneficially owned 2,227,427 shares of 89bio, Inc., representing approximately 1.9% of the outstanding shares.
- Biotechnology Value Fund II, L.P. (BVF2) beneficially owned 1,799,517 shares, equating to approximately 1.5% of the outstanding shares.
- Biotechnology Value Trading Fund OS LP beneficially owned 223,979 shares, representing approximately 0.2% (less than 1%) of the outstanding shares.
- BVF GP Holdings LLC, as the sole member of BVF I GP LLC and BVF II GP LLC, may be deemed to beneficially own 4,026,944 shares, or approximately 3.4% of the outstanding shares.
- BVF Partners L.P., BVF Inc., and Mark N. Lampert collectively may be deemed to beneficially own 4,333,885 shares, representing approximately 3.6% of the outstanding shares, which includes 82,962 shares held in a Partners managed account.
- The percentages are based on 119,788,102 shares of 89bio, Inc. common stock outstanding as of November 12, 2024, as reported by the Issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure by an investment fund regarding its passive ownership stake in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that investment funds like Biotechnology Value Fund are active in the biotech sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, confirming the ownership structure and the passive nature of the investment (not for control or influence).
Key Dates
| Date | Description |
|---|---|
| 2024-11-12 | Date as of which 89bio, Inc. reported 119,788,102 shares outstanding in its Prospectus Supplement. |
| 2024-12-31 | Date of event which requires the filing of this statement, reflecting the beneficial ownership. |
| 2025-02-14 | Date the Schedule 13G Amendment No. 4 was signed and filed. |
Keywords
89bio Inc., Biotechnology Value Fund, SEC filing, Schedule 13G, beneficial ownership, institutional investor, biotechnology, investment fund, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.